Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease
Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease
复制标题
帕金森病运动障碍和非运动障碍患者体内腺苷 2A 受体的可用性
DOI：
10.1212/wnl.0b013e31821ccce4
复制
发表时间：
2011-05-01
期刊：
影响因子：
9.9
通讯作者：
Brooks, D. J.
中科院分区：
文献类型：
--
作者：
Ramlackhansingh, A. F.;Bose, S. K.;Brooks, D. J.
目的：研究帕金森病（PD）伴或不伴左旋多巴诱导的运动障碍（LIDS）患者纹状体腺苷A2 A受体的可用性。在有效缓解PD运动症状的同时，长期使用左旋多巴与LID的发展相关。A2 A受体表达于间接通路介质棘状纹状体神经元的体部和多巴胺终末上，并在调节多巴胺传递中起作用。A2 A拮抗剂通过增强左旋多巴的功效而具有抗帕金森病活性。我们的目的是研究A2 A受体的可用性与PD患者和不LIDs使用PET和[C-11] SCH 442416，A2 A antagonist.Methods：6例PD患者和6例无LIDs进行了研究退出12小时的药物治疗。将他们的PET结果与6名年龄匹配的健康对照进行比较。使用光谱分析，计算尾状核、壳核和丘脑的[C-11] SCH 442416区域分布容积（V-T），并比较两组之间反映特异性：非特异性摄取比率的结合电位（BPND）。患有PD的LIDS受试者的尾状核和壳核中的A2 A结合要高得多（分别为p = 0.026和p = 0.036），而无LID的PD受试者的受试者处于对照范围内。丘脑A2 A的可用性是相似的所有3 groups.Conclusion：PD与LIDS患者表现出纹状体A2 A受体的可用性增加。这一发现与腺苷传递改变在LIDS中发挥作用是一致的，并为A2 A受体药物治疗这些运动并发症的试验提供了理论基础。神经病学（R）2011;76：1811-1816
Objective: To investigate striatal adenosine A2A receptor availability in patients with Parkinson disease (PD) with and without levodopa-induced dyskinesias (LIDs). While providing effective relief from the motor symptoms of PD, chronic levodopa use is associated with development of LIDs. A2A receptors are expressed on the bodies of indirect pathway medium spiny striatal neurons and on dopamine terminals and play a role in modulating dopamine transmission. A2A antagonists have antiparkinsonian activity by boosting levodopa efficacy. We aimed to study A2A receptor availability in patients with PD with and without LIDs using PET and [C-11]SCH442416, an A2A antagonist.Methods: Six patients with PD with and 6 without LIDs were studied withdrawn 12 hours from medication. Their PET findings were compared with 6 age-matched healthy controls. Using spectral analysis, [C-11] SCH442416 regional volumes of distribution (V-T) were computed for the caudate, putamen, and thalamus and binding potentials (BPND) reflecting the ratio of specific: nonspecific uptake were compared between groups.Results: A2A binding in the caudate and putamen of subjects with PD with LIDs was far higher (p = 0.026 and p = 0.036, respectively) than that of subjects with PD without LIDs, which lay within the control range. Thalamic A2A availability was similar for all 3 groups.Conclusion: Patients with PD with LIDs show increased A2A receptor availability in the striatum. This finding is compatible with altered adenosine transmission playing a role in LIDs and provides a rationale for a trial of A2A receptor agents in the treatment of these motor complications. Neurology (R) 2011;76:1811-1816